EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort

Roberta Ramonda, Mariagrazia Lorenzin, Maria Sole Chimenti, Fabiola Atzeni, Angelo Semeraro, Salvatore D'Angelo, Carlo Selmi, Augusta Ortolan, Antonio Marchesoni, Maria Manara, Michele Maria Luchetti Gentiloni, Leonardo Santo und 14 weitere

Arthritis Research & Therapy · 28.09.2024 · 26 (1)

DOI: 10.1186/s13075-024-03401-x ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Arthritis Research & Therapy, online erschienen am 28.09.2024. Verfasst von Roberta Ramonda und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine DIMED, Rheumatology Unit, University of Padova, Padova, Veneto, Italy. roberta.ramonda@unipd.it. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Arthritis, Psoriatic. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Padova.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives to evaluate over a 48-month follow-up period the: 1) long-term effectiveness and safety; 2) drug retention rate (DRR); 3) impact of comorbidities and bDMARDs line on MDA and DAPSA remission/low disease activity (LDA) of secukinumab in a multicenter Italian cohort of PsA patients.

Methods

Consecutive PsA patients receiving secukinumab were followed prospectively in Italian centers between 2016 and 2023. Disease characteristics, previous/ongoing treatments, comorbidities and follow-up duration were recorded. Treatment response was evaluated at 6 and 12 months after initiation, and every year up to 48 months (T48). DRR was assessed according to clinical and demographic features, comorbidities and bDMARDs line. Adverse events (AE) were recorded.

Results

Six hundred eighty-five patients [42.5% male] were enrolled; 32.9% naïve received secukinumab; 74.2% had ≥ 1 comorbidity. Overall, secukinumab yielded improved outcomes at T48: naïve maintained lower disease activity vs. non-naïve [DAPSA 4.0 (1.4–8.1) vs. 6.0 (2.2–10.4); p = 0.04]; 76.9% naïve and 66.2% non-naïve achieved MDA; MDA no comorbidities vs. 1–3 comorbidities 78.8% vs. 73.3% ( p < 0.05), and MDA no comorbidities vs. > 3 comorbidities 78.8% vs. 48.7% ( p < 0.001). DAPSA-REM and DAPSA-LDA rates were higher in naïve patients, albeit similar between those without comorbidities vs. 1–3 comorbidities, and slightly lower in those with > 3 comorbidities. Treatment was discontinued in 233 patients due to loss of effectiveness, and in 41 due to AE. The overall DRR at T48 was 66%, with differences according to bDMARDs line ( p < 0.001), use of combined csDMARDs ( p = 0.016), BMI ( p = 0.037) and mono/oligoarthritis vs. polyarthritis ( p = 0.012).

Conclusions

Secukinumab proved safe and effective, and patients achieved sustained remission with a notable drug retention rate at 4 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedArthritis, PsoriaticAdultAgedFemaleHumansMaleMiddle AgedAntirheumatic AgentsCohort StudiesFollow-Up StudiesItalyProspective StudiesTreatment Outcome

Stichwörter der Autor:innen

BiologicsDrug retention ratePsoriatic arthritisRemission/EffectivenessSafetySecukinumab

Substanzen

Antibodies, Monoclonal, HumanizedAntirheumatic Agentssecukinumab

Autor:innen und Institutionen

  • Department of Medicine DIMED, Rheumatology Unit, University of Padova, Padova, Veneto, Italy. roberta.ramonda@unipd.it.
  • Rheumatology Unit, Department of Medicine-DIMED, Padova University Hospital, Via Giustiniani, 2, 35128, Padova, Italy. roberta.ramonda@unipd.it.
  • Department of Medicine DIMED, Rheumatology Unit, University of Padova, Padova, Veneto, Italy.
  • Department of Systems Medicine, Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, Rome, Lazio, Italy.
  • Rheumatology Unit, University of Messina, Messina, Sicilia, Italy.
  • Rheumatology Unit, Martina Franca-ASL Taranto, Martina Franca Hospital, Martina Franca, Taranto, Puglia, Italy.

Förderung

  • Università degli Studi di Padova

Zitieren

APA

Ramonda, R., Lorenzin, M., Chimenti, M. S., Atzeni, F., Semeraro, A., D'Angelo, S., Selmi, C., Ortolan, A., Marchesoni, A., Manara, M., Luchetti Gentiloni, M. M., Santo, L., Salvarani, C., Cauli, A., Rossini, M., Amato, G., Cozzi, G., Scagnellato, L., Ferraioli, M., …, & on behalf Spondyloarthritis and Psoriatic Arthritis SIR Study Group “Antonio Spadaro” (2024). Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort. Arthritis Research & Therapy, 26(1). https://doi.org/10.1186/s13075-024-03401-x

Vancouver

Ramonda R, Lorenzin M, Chimenti MS, Atzeni F, Semeraro A, D'Angelo S, et al. Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort. Arthritis Research & Therapy. 2024;26(1). doi:10.1186/s13075-024-03401-x

BibTeX
@article{Ramonda2024,
  author = {Ramonda, Roberta and Lorenzin, Mariagrazia and Chimenti, Maria Sole and Atzeni, Fabiola and Semeraro, Angelo and D'Angelo, Salvatore and Selmi, Carlo and Ortolan, Augusta and Marchesoni, Antonio and Manara, Maria and Luchetti Gentiloni, Michele Maria and Santo, Leonardo and Salvarani, Carlo and Cauli, Alberto and Rossini, Maurizio and Amato, Giorgio and Cozzi, Giacomo and Scagnellato, Laura and Ferraioli, Mario and Carriero, Antonio and Fracassi, Elena and Giorgio, Francesco and Doria, Andrea and Foti, Rosario and Carletto, Antonio and on behalf Spondyloarthritis and Psoriatic Arthritis SIR Study Group “Antonio Spadaro”, on behalf Spondyloarthritis and Psoriatic Arthritis SIR Study Group “Antonio Spadaro”},
  title = {Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort},
  journal = {Arthritis Research & Therapy},
  year = {2024},
  volume = {26},
  number = {1},
  doi = {10.1186/s13075-024-03401-x}
}
Kostenlos starten →